A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, at least 18 years of age, inclusive
Diagnosis of rheumatoid arthritis of at least 6 months duration
Moderate to severe active rheumatoid arthritis (DAS28 \>/=3.2)
Patients received at least 1 disease-modifying anti-rheumatic drug (DMARD) and/or 1 or more TNFalfa-inhibitors over a period of at least 8 weeks
You may not be if
Major surgery (including joint surgery) within 8 weeks prior to screening or planned surgery within 6 months following randomization
Rheumatic autoimmune disease other than rheumatoid arthritis
Prior history of or current inflammatory joint disease other than rheumatoid arthritis
Functional class IV (ACR criteria)
History of severe allergic reaction to human, humanized or murine monoclonal antibodies
Known active current or history of recurrent infection (including tuberculosis)
Primary or secondary immunodeficiency (history of or currently active)
Body weight \>150 kg
Previous treatment with any cell-depleting therapies
Previous treatment with tocilizumab
Clareo Health | A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment
